1 Min Read
Nov 7 (Reuters) - Mabvax Therapeutics Holdings Inc
* Mabvax Therapeutics receives U.S. Patent for its clinical stage humab-5b1 antibody Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.